hotspot -WSS

hotspot

author：entertainment 2025-09-27 16:35:48 - browse：87

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Cholera vaccine supply gets boost as demand surges globally

focus

WSS

Sanofi strikes deal with Novavax, boosting the vaccine maker

Telehealth startups turn to complex chronic diseases

H5N1 communication has been strictly for the birds

Sanofi strikes deal with Novavax, boosting the vaccine maker

Study: Adult vaccinations pay for themselves in societal benefits

Researchers on aging grapple with how to calculate biological age

explore

hotspot

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

Wikipedia

Psychedelics group wrestles with new pharma identity

FTC falls short on scrutinizing hospital mergers, study says

Supreme Court strikes down use of affirmative action

CDC wastewater surveillance dashboard to track bird flu hotspots

Supreme Court strikes down use of affirmative action

Making AI in medicine accessible to smaller, and rural hospitals

Jerome Adams on the need for new antivirals for Covid

Cue Health's Covid

Drug repurposing or repositioning? The language matters

UnitedHealth financials solid despite Change Healthcare cyberattack

focus

Cell therapy fails to slow type 1 diabetes, but safety is established

Close Medicare's dangerous gaps in addiction treatment coverage

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Cell therapy fails to slow type 1 diabetes, but safety is established

H5N1 bird flu: what we're starting to learn about infection in cows

Exact Sciences stock tumbles despite strong cancer detection sales

hotspot

Wikipedia

focus

focus